GSK announced on 31 March 2009 its reception of European Commission authorisation for Synflorix, a paediatric pneumococcal vaccine to protect against life-threatening diseases such as meningitis and bacteraemic pneumonia, as well as middle ear infections.
GSK’s new vaccineis indicated for active immunisation against invasive disease and acute otitis media (AOM) caused by Streptococcus pneumoniae in infants and children from six weeks up to two years of age.
Invasive pneumococcal diseases (IPD) caused by S. pneumoniae include meningitis, bacteraemia (blood infections), and bacteraemic pneumonia.
By providing increased protection against three additional strains of bacteria associated with severe disease, Synflorix may help prevent more of these life-threatening infections than the currently licensed pneumococcal vaccine.
It also offers protection against middle ear infection casused by S. pneumoniae, a condition that affects many children and their families in Europe.<헬스코리아뉴스>
저작권자 © 헬스코리아뉴스 무단전재 및 재배포 금지
